Evidence map›Paper›PMID 29109117›Full record

Trial reportCancer prevention research (Philadelphia, Pa.)2018

Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia.

Don A Delker, Austin C Wood, Angela K Snow, N Jewel Samadder, Wade S Samowitz, Kajsa E Affolter, Kenneth M Boucher, Lisa M Pappas, Inge J Stijleman, Priyanka Kanth and 4 more

Open access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Cancer prevention research (Philadelphia, Pa.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Primary and Secondary Prevention Interventions to Reduce Risk Factors Associated with Colorectal Cancer in High-Risk Groups: a Systematic Literature Review.Journal of cancer education : the official journal of the American Association for Cancer Education · 2023
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Erlotinib suppresses tumorigenesis in a mouse model of colitis-associated cancer.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2024
    Article
  6. Identification of driving genes of familial adenomatous polyposis by differential gene expression analysis and weighted gene co-expression network analysis.Technology and health care : official journal of the European Society for Engineering and Medicine · 2024
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Don A DelkerDepartment of Internal Medicine, University of Utah, Salt Lake City, Utah.
Austin C WoodHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
Angela K SnowHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
N Jewel SamadderDepartment of Internal Medicine, University of Utah, Salt Lake City, Utah.
Wade S SamowitzHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
Kajsa E AffolterHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
Kenneth M BoucherDepartment of Internal Medicine, University of Utah, Salt Lake City, Utah.
Lisa M PappasHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
Inge J StijlemanHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
Priyanka KanthDepartment of Internal Medicine, University of Utah, Salt Lake City, Utah.
Kathryn R ByrneDepartment of Internal Medicine, University of Utah, Salt Lake City, Utah.
Randall W BurtDepartment of Internal Medicine, University of Utah, Salt Lake City, Utah.
Philip S BernardHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
Deborah W NeklasonDepartment of Internal Medicine, University of Utah, Salt Lake City, Utah. Deb.neklason@hci.utah.edu.
University of Utah · USHuntsman Cancer Institute · US

Funding

UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI KATHARINE S ULLMAN · 1986 to 2026
$72.6M
TCF/LEF function during intestinal maintenance and colon tumorigenesisP01CA073992 · NCI · UNIVERSITY OF UTAH · PI BURT, RANDALL WALTER · 1998 to 2014
$29.7M
Clinical Research Curriculum AwardK30TR000106 · NCATS · UNIVERSITY OF MARYLAND BALTIMORE · PI ROGHMANN, MARY-CLAIRE · 2012 to 2012
$297k
NCATS NIH HHS K30 TR000106NCI NIH HHS HHSN261201000131CNCI NIH HHS HHSN261201200013INCI NIH HHS HHSN261201200031CNCI NIH HHS P01 CA073992NCI NIH HHS P30 CA042014
6 · The paper itself

Abstract

To identify gene expression biomarkers and pathways targeted by sulindac and erlotinib given in a chemoprevention trial with a significant decrease in duodenal polyp burden at 6 months (

Indexed as

Adenomatous Polyposis ColiAdultAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCyclooxygenase 1Duodenal NeoplasmsErbB ReceptorsErlotinib HydrochlorideFemaleFollow-Up StudiesGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPrognosisBiomarkers, TumorCyclooxygenase 1EGFR protein, humanErbB ReceptorsErlotinib HydrochloridePTGS1 protein, humanRNA, MessengerSulindac

Identifiers

PMID29109117
PMCPMC5754246
OpenAlexW2767521655

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.